In the EU, more than seven million people are estimated to have dementia. 1 An ageing population will lead to an increase in dementia cases, 1 with prevalence rates in both western and eastern Europe expected to at least double by 2040. 2 Worldwide, it is forecast that one in 85 people will be living with Alzheimer's disease (AD) by 2050. 3 In Europe, AD is the most common form of dementia, accounting for approximately two-thirds of cases. 4 It is suggested that about half of dementia cases remain undiagnosed; 2,5 however, rates of missed diagnosis or under-recognition vary, and a large proportion (up to 90%) of patients with mild disease remain undiagnosed. 6,7 Several reasons have been cited for this lack of recognition, including a lack of awareness among care-givers of the symptoms of Alzheimer's dementia, a lack of recognition of Alzheimer's dementia by physicians and late referral of patients to a specialist. 8 As primary care physicians play a crucial role in the identification, diagnosis and overall management of patients with dementia, their interface with secondary care is of great significance.
3
In Europe, AD is the most common form of dementia, accounting for approximately two-thirds of cases. 4 It is suggested that about half of dementia cases remain undiagnosed; 2,5 however, rates of missed diagnosis or under-recognition vary, and a large proportion (up to 90%) of patients with mild disease remain undiagnosed. 6, 7 Several reasons have been cited for this lack of recognition, including a lack of awareness among care-givers of the symptoms of Alzheimer's dementia, a lack of recognition of Alzheimer's dementia by physicians and late referral of patients to a specialist. 8 As primary care physicians play a crucial role in the identification, diagnosis and overall management of patients with dementia, their interface with secondary care is of great significance.
Alzheimer's dementia is the consequence of a degenerative disorder and has an insidious onset. In both sporadic and familial AD, genetic mutations and genetic risk factors will be present at birth. However, multiple environmental factors interact with the ageing process and genetic vulnerability to determine the age at onset of disease and, Beyond the cognitive symptoms and functional consequences of these symptoms, patients often develop distressing neuropsychiatric symptoms. The study of apathy and passiveness in Alzheimer's dementia and other neuropsychiatric symptoms has been a topic of growing interest among clinicians and researchers. 16, 17 Apathy is the most frequent behavioural change occurring in Alzheimer's dementia and mild cognitive impairment. 19 It has now been established that apathy is typically the earliest neuropsychiatric symptom to manifest in AD, pre-dating the onset of dementia, and that it worsens steadily throughout the course of the illness. 19, 20 The relationship between apathy and level of cognitive impairment appears to move in concert. 20 Apathy is thus an early consequence of AD and may be more observable than subtle cognitive decline. Therefore, individuals who display both apathy and cognitive impairment may be demonstrating early clinical features of AD and hence are at high risk of developing dementia. 21 Given the prominence of this neuropsychiatric symptom, a task force was convened in 2008 to reach agreement on criteria for apathy given that it is a symptom of many medical and other psychiatric diagnoses.
The task force defined apathy as diminished motivation that persists over time (present for at least four weeks) and a reduction in goaldirected behaviour, goal-directed cognitive activity and/or emotions. 16 Furthermore, apathy is now recognised as a primary contributing factor mediating functional decline. 21 The
Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
states that in order to make a diagnosis of Alzheimer's dementia, there has to be an impaired ability to learn new information or recall previously learned information, accompanied by other cognitive impairments such as aphasia. These cognitive deficits must also cause significant impairments in social or occupational functioning and represent a significant decline from a previous level of functioning. The course of the disease is a progressive decline. 22 Other classifications are similarly biased towards the clinical phenotype.
While these criteria and other guidelines may be important for facilitating a timely diagnosis of dementia, they have been shown to be infrequently used and not always available -a particularly prominent problem in primary care or non-specialist settings. The underrecognition of Alzheimer's dementia in these situations may well be mediated by a lack of knowledge of or reference to diagnostic criteria.
In terms of care pathways that arise on the basis of a diagnosis being made, one study exploring the primary care diagnosis of dementia in Europe showed that referral pathways often depended on the individual healthcare systems and that diagnostic strategies differed on the basis of varied cultural influences. The study identified that there needs to be a focus on timely diagnosis and that guidelines for this need to be developed and implemented. Following this, referral pathways from primary to secondary care, as well as diagnostic strategies in both of these settings, which will include collaboration among medical professionals, need to be identified. In this regard 'timely diagnosis' is defined as 'the time when the patient or care-giver and the primary care physician recognise that a dementia syndrome may be developing'.
Timely diagnosis implies that methodologies should concentrate not on population screening, but on a speedy response to the first reported signs of changed behaviour and functioning in the patient. 23 The implications of screening a well population mean that we are not yet ready for this approach. However, patients seeking help for a cognitive problem expect accurate initial assessment. It may be that initial case ascertainment in primary care has high sensitivity for there being a possible neurodegenerative illness and that the specificity of diagnosis need only be achieved in secondary care, where more targeted assessments and investigations can be undertaken where appropriate.
Although much work still needs to be carried out researching the most accurate and effective mechanism to effect a good referral from primary to secondary care, primary care physicians should still be encouraged to take the simple steps of excluding a medical co-morbidity -for example an occult infection or thyroid disorder -as the aetiology for the cognitive impairment. It is also worthwhile for general practitioners to undertake some basic cognitive testing.
There have been numerous brief cognitive screens developed for use in non-specialist settings. Undoubtedly, the two tests that predominate and can be applied in primary care are the MMSE and clock-drawing test (CDT).
The MMSE was one of the first cognitive tests to be developed and has subsequently found common usage in assessing patients with dementia. 24 While it may not have the psychometric properties of more elaborate tests, it is simple to apply and has good face validity.
However, it is affected by patient education level, has an over-reliance on verbal assessment of memory and has very low specificity for the underlying neurological disorders. 24, 25 Moreover, sensitivity for detecting early-stage Alzheimer's dementia can be as low as 31%. 25 Recognising Early Symptoms of Alzheimer's Disease in Routine Clinical Practice
The CDT taps into a wide range of cognitive abilities, including executive functions. It has high sensitivity for detecting Alzheimer's dementia and specificity for differentiating this from other dementias, and shows high levels of inter-rater and test-re-test reliability as well as good positive predictive value, despite significant variability in the scoring systems. 26 The CDT has been shown to be a very efficient screening test for mild to moderate Alzheimer's dementia and may be useful for the early detection of this. It has low false-negative and false-positive rates, especially if scored according to the Shulman scale and combined with the MMSE and informant reports. 26, 27 In primary care there is limited scope for applying what remain expensive tests, such as magnetic resonance imaging (MRI) scanning or plasma markers. These tests remain for the most part at the near horizon of application, awaiting the results of conclusive definition of their accuracy -a process being assisted by the recent establishment of a Cochrane Collaboration group dedicated to this task. However, a good referral will be made when the primary care physician recognises the risk that AD may be mediating the cognitive complaints and performs some bedside cognitive tests.
In summary, the near future will see us expecting to be able to diagnosis AD earlier and earlier in its course, certainly well before dementia develops. However, we remain poor at diagnosing Alzheimer's dementia even when behavioural, cognitive and functional symptoms and features are clearly manifest. Awareness of
the diagnosis, what features should constitute concern and a belief that there is good reason from a biopsychosocial perspective to make the diagnosis will mediate better, earlier and more effective management of patients with AD. n
